Atrial fibrillation prevalence is rising across socioeconomic strata globally, the new analysis finds, with effects of BMI, ETOH, and sedentary behavior shifting as key drivers.
Oldest and most frail elderly were at more than 60% greater risk of bleeding when switched from a VKA than those who remained on the traditional agent.
The reduction in risk of CV events, the first to be shown by an antiobesity drug, was higher than expected and could help alter perceptions of the agents as "lifestyle drugs."